Author name: Yali Friedman

Financial Snapshot For October 2003 Stocks On New Plateau

Vatican steps in on biotech foods debate The Vatican stepped into the charged debate over genetically modified food on Monday,

A survey of strategic licensing practices in the pharmaceutical industry Alliances often appear to be a relatively cost-effective and rapid

The Generic Retribution The generic industry has always been overshadowed by branded pharmaceuticals. The government policies and the mandate have

October sees a frenzy of biotech IPOs October was the busiest month in three years for initial public offerings in

Venture Financing: Ready To Rebound? There’s little doubt that the financing window has opened up, but investors, analysts and biotech

Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries A new Wharton study comparing average prices

Gene Tests? Not So Fast The U.S. Food and Drug Administration Monday released draft guidelines regarding how genetic data could

States flock to biotech like gamblers to lottery tickets Florida lawmakers last month approved a $310 million biotech research center

In Initial Finding, FDA Calls Cloned Animals Safe as Food Milk and meat from cloned animals are safe to consume,